J Drugs Dermatol. 2020 Apr 1;19(4):s5-15.
Since initial US Food and Drug Administration approval of botulinum toxin type A (BoNT-A) for aesthetic use in 2002, clinical evidence and experience with BoNT-A and understanding of facial anatomy have greatly increased, leading to rapid advances in treatment planning and implementation. BoNT-A use has expanded from the upper face to the midface, lower face, and neck, so that BoNT-A injection is the most common cosmetic procedure worldwide. Trends in facial aesthetics reflect growing patient diversity with respect to age, gender, and ethnicity. In October 2019, a multidisciplinary panel of 6 experts in minimally invasive injectable procedures in the specialties of dermatology and plastic surgery convened at the 2019 American Society for Dermatologic Surgery (ASDS) meeting in Chicago, IL. Their goal was to discuss recent advances in BoNT-A use in facial aesthetics, including implications of the introduction of new agents in light of an evolving patient population. J Drugs Dermatol. 2020;19(4 Suppl 1):s5-15 To receive a CME certificate of participation, you should: •Read the entire publication, including the CME information. •Register or log in at www.paradigmmc.com/822 to complete and submit the online posttest and evaluation. Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately.
自 2002 年美国食品和药物管理局（FDA）首次批准肉毒毒素 A 型（BoNT-A）用于美容用途以来，临床证据和 BoNT-A 的经验以及对面部解剖结构的理解有了极大的提高，这导致了治疗计划和实施的迅速发展。BoNT-A 的使用范围已从上面部扩展到中面部、下面部和颈部，因此 BoNT-A 注射是全球最常见的美容程序。面部美学的趋势反映了患者在年龄、性别和种族方面的多样性不断增加。2019 年 10 月，在伊利诺伊州芝加哥举行的 2019 年美国皮肤外科学会（ASDS）会议上，来自皮肤科和整形手术微创注射专业的 6 名专家组成的多学科小组齐聚一堂。他们的目标是讨论 BoNT-A 在面部美学中的最新应用进展，包括鉴于不断变化的患者群体，新制剂的引入所带来的影响。J Drugs Dermatol. 2020;19(4 Suppl 1):s5-15 要获得参与 CME 证书，您应该： •阅读整篇文章，包括 CME 信息。 •注册或登录 www.paradigmmc.com/822 以完成并提交在线测试和评估。在线完成测试和评估后，将立即提供参与证书以供下载/打印。
